Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9-valent HPV vaccine in females previously vaccinated with Gardasil
2009-015500-26Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2009
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human papillomavirus infection comparing V503 with Placebo (2 arms). Primary endpoints: Safety and tolerability and Immunogenicity against HPV types 31, 33, 45, 52, and 58. Started Dec 2009; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2009-015500-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015500-26.